insight
✂️ 성형 🏥 중증 🌐 전체
← 뒤로

MRI-Based Quantification of Intratumoral Heterogeneity Predicts Response in Hepatocellular Carcinoma Treated with Atezolizumab-Bevacizumab and TACE/HAIC.

1/5 보강
Academic radiology 📖 저널 OA 5.8% 2023: 1/1 OA 2024: 1/8 OA 2025: 4/67 OA 2026: 3/79 OA 2023~2026 2025 Vol.32(11) p. 6451-6462
Retraction 확인
출처
PubMed DOI

PICO 자동 추출 (휴리스틱, conf 3/4)

유사 논문
P · Population 대상 환자/모집단
88 patients (58.
I · Intervention 중재 / 시술
atezolizumab-bevacizumab combined with TACE/HAIC at multiple centers were enrolled between January 2019 and January 2024
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
[CONCLUSION] The MRI-based ITH score, when combined with clinical and radiomic features, provides a robust predictive tool for treatment response in HCC patients undergoing atezolizumab-bevacizumab combined with TACE/HAIC. [DATA AVAILABILITY STATEMENT] The datasets generated or analyzed during the study are available from the corresponding author on reasonable request.

Yan HT, Zu QQ, Hua HJ, Fan WL, Cheng Y, Liu S, Shi HB, Feng ZL, Zhang JX

PubMed ↗ DOI ↗ BibTeX ↓ RIS ↓
📝 환자 설명용 한 줄

[RATIONALE AND OBJECTIVES] Hepatocellular carcinoma (HCC) is highly heterogeneous, resulting in different treatment responses to anti-tumor therapy.

🔬 핵심 임상 통계 (초록에서 자동 추출 — 원문 검증 권장)
  • 표본수 (n) 151
  • p-value p < 0.001

이 논문을 인용하기

↓ .bib ↓ .ris
APA Yan HT, Zu QQ, et al. (2025). MRI-Based Quantification of Intratumoral Heterogeneity Predicts Response in Hepatocellular Carcinoma Treated with Atezolizumab-Bevacizumab and TACE/HAIC.. Academic radiology, 32(11), 6451-6462. https://doi.org/10.1016/j.acra.2025.06.025
MLA Yan HT, et al.. "MRI-Based Quantification of Intratumoral Heterogeneity Predicts Response in Hepatocellular Carcinoma Treated with Atezolizumab-Bevacizumab and TACE/HAIC.." Academic radiology, vol. 32, no. 11, 2025, pp. 6451-6462.
PMID 40617706 ↗
DOI 10.1016/j.acra.2025.06.025

Abstract

[RATIONALE AND OBJECTIVES] Hepatocellular carcinoma (HCC) is highly heterogeneous, resulting in different treatment responses to anti-tumor therapy. The present study aimed to investigate the prognostic value of noninvasive MRI-based intratumoral heterogeneity (ITH) quantification for predicting treatment response to atezolizumab-bevacizumab combined with transarterial chemoembolization (TACE) /hepatic artery infusion chemotherapy (HAIC) in unresectable HCC.

[MATERIALS AND METHODS] Patients with unresectable HCC (n=151) who received atezolizumab-bevacizumab combined with TACE/HAIC at multiple centers were enrolled between January 2019 and January 2024. Conventional and habitat radiomic features were extracted from MRI to construct the ITH score. Predictive models based on clinical variables, radiomic features, and the ITH score were developed and evaluated using the area under the receiver operating characteristic curve (AUC).

[RESULTS] 88 patients (58.3%) showed a response to atezolizumab-bevacizumab combined with TACE/HAIC. The combined model integrating clinical variables, radiomic features, and the ITH score achieved the highest accuracy in predicting treatment response to triple therapy with an AUC of 0.971, 0.937, and 0.868 in the training, validation, and testing cohort, respectively. Furthermore, the combined model can categorize patients into high-risk and low-risk groups for progression-free survival (PFS) and overall survival (OS) in the training (p < 0.001 for PFS and OS), validation (p < 0.001 for PFS and OS) and testing cohort (p = 0.005 for PFS; p < 0.001 for OS).

[CONCLUSION] The MRI-based ITH score, when combined with clinical and radiomic features, provides a robust predictive tool for treatment response in HCC patients undergoing atezolizumab-bevacizumab combined with TACE/HAIC.

[DATA AVAILABILITY STATEMENT] The datasets generated or analyzed during the study are available from the corresponding author on reasonable request.

🏷️ 키워드 / MeSH 📖 같은 키워드 OA만

🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반